ArticleJournal of translational medicine2026
From metabolic dysregulation to clinical alert: a novel panel of biomarkers for staging alcohol-associated liver disease.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
BACKGROUND AND
aimALD is among the most prevalent chronic liver disorders with rising global incidence, the aim of our study is to evaluate the effect of metabolites in the progress of ALD, and build a prediction model for ALC.
methodsA total of 161 subjects were prospectively enrolled and classified into HC, AUD, AH, ALC. Plasma samples underwent untargeted LC-MS/MS metabolomics analysis. Data were split into training, validation and test sets at a 6:2:2 ratio. Partial least squares discriminant analysis and random forest were employed for feature selection, followed by logistic regression to build metabolite-based and metabolite-plus-clinical composite models. Discrimination was evaluated by AUC, sensitivity, specificity and accuracy.
resultsMetabolomic profiles showed progressive separation among groups (Q² > 0.65 for all PLS-DA models). Five metabolites (Vecuronium, N-Docosahexaenoyl Cysteine, 7-Acetylintermedine, Hymenoxon, E-3174) were identified as the most influential features for distinguishing ALC from HC, yielding an AUC of 0.986 (95% CI: 0.969-0.999) in the validation set and 100% accuracy in the test set. Integration of these metabolites with AST further elevated the AUC to 0.998 with 96.70% sensitivity and 100% specificity. Similarly, a five-metabolite panel plus PT achieved perfect accuracy (AUC = 0.964) in discriminating ALC from AH.
conclusionsWe delineate stage-specific metabolic fingerprints of ALD and present robust, non-invasive models for early identification of cirrhosis. Incorporating metabolomic biomarkers with routine clinical variables markedly improves diagnostic precision and offers a practical tool for risk stratification and personalized management of alcohol-related liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.